エピソード
-
The recent ECTRIMS 2024 in Copenhagen showcased the work of young scientific investigators, including this year's ECTRIMS Fellowship recipients Oscar Ayala from Colombia and Zuhal Abasiyanik from Turkey. Every year, ECTRIMS awards fellowships across various categories to promote knowledge and expertise in the field of multiple sclerosis (MS). Oscar and Zuhal spoke with host Brett Drummond of MSTranslate about the research projects that they will be pursuing and how they believe this opportunity will impact their career.
The ECTRIMS Fellowship application period for the 2025 cycle is now open. Apply before the deadline of December 1, 2024 at 23:59 CET.
-
Nearly three million people worldwide are living with multiple sclerosis (MS), affecting individuals from diverse geographical, ethnic, racial, and socio-economic backgrounds. This diversity raises important questions about how these factors may influence the experiences and outcomes of those with MS, as well as whether research studies and clinical trials have sufficiently addressed this variability. To answer these questions and more, host Brett Drummond of MSTranslate speaks with two leading researchers in this field: Dr. Léorah Freeman, assistant professor at the Dell Medical School Department of Neurology, The University of Texas at Austin; and Dr. Lilyana Amezcua, Associate Professor of Clinical Neurology at the University of Southern California's Keck School of Medicine.
-
エピソードを見逃しましたか？
-
While paediatric onset multiple sclerosis is relatively rare, it presents unique challenges. Extensive research efforts are taking place around the world to better understand the disease mechanism of paediatric MS and the similarities and differences that exist with adult onset MS to help determine the best treatment options for children and adolescents. In this episode, host Brett Drummond of MSTranslate explores the topic with Dr. Yael Hacohen of Great Ormond Street Hospital for Children and UCL Institute of Neurology in the UK and Dr. Thaís Armangué of SJD Barcelona Children's Hospital in Spain.
-
If you talk to someone living with MS about their journey, one of the first things they will tell you is that they knew something was wrong long before they received their diagnosis. While this anecdotal evidence has been commonly discussed, it was only relatively recently that the research world has started to investigate this concept. Through this work, the idea of an MS prodrome has been studied, with potential implications for early diagnosis and treatment. Host Brett Drummond of MSTranslate speaks with Prof. Helen Tremlett of the University of British Columbia, a leading expert in recognising and investigating the MS prodrome.
-
Significant progress has been made in multiple sclerosis (MS) treatments over the past 20 years. What does the next 20 years hold for MS therapies? What novel targets are being investigated? What clinical trials are in the pipeline and when can we expect new medications in the market? Host Brett Drummond of MS Translate explores these questions and more with Prof. Heinz Wiendl of University of Freiburg and Prof. Ludwig Kappos of University Hospital Basel.
-
Nurses play a specialised and unique role in the journey of people living with multiple sclerosis (MS). At ECTRIMS 2024, MS nurses showcased their experiences and insights into how to effectively support patients. In this episode, host Brett Drummond of MSTranslate talks with veteran MS nurses K-J Lazarus of Austin Health in Australia and Fiona d'Young of the Auckland Hospital in New Zealand.
-
The Patient Community Day of ECTRIMS 2024 brought together people living with multiple sclerosis (MS), medical professionals, researchers, and advocates in two interactive sessions. They explored the forefront of MS research and treatment, focusing on groundbreaking topics like remyelination and myelin repair. They disussed promising new therapies that could revolutionise patient care, along with practical lifestyle changes and effective symptom management strategies.
In Part II of our Patient Community Day episode, host Brett Drummond of MSTranslate talks to Sumaira Ahmed and Trevis Gleason, who are living with NMOSD and MS, respectively, about their experience attending the event.
-
The Patient Community Day of ECTRIMS 2024 brought together people living with multiple sclerosis (MS), medical professionals, researchers, and advocates in two interactive sessions. They explored the forefront of MS research and treatment, focusing on groundbreaking topics like remyelination and myelin repair. They disussed promising new therapies that could revolutionise patient care, along with practical lifestyle changes and effective symptom management strategies.
In Part 1 of our Patient Community Day episode, Elisabeth Kasilingam, Chief Executive Officer of the European Multiple Sclerosis Platform (EMSP) and Vice President of the European Patients’ Forum, talks with host Brett Drummond of MSTranslate about bridging the gap between patients, clinicians, and the scientific community.
-
Former ECTRIMS President and MS Journal Editor-in-Chief Alan Thompson and host Brett Drummond wrap up the last day of ECTRIMS 2024 with their final thoughts and insights.
-
Anne Helme, Head of Research at MSIF, and host Brett Drummond discuss the key takeaways unveiled on the second day of ECTRIMS 2024 in Copenhagen, as well as the value of global collaboration.
-
ECTRIMS Vice President Bruno Stankoff highlights the most relevant insights from day one of ECTRIMS 2024 in Copenhagen, and provides a glimpse of what to expect from the ECTRIMS society in the coming year.
-
Listen to Romain Marignier from CHU de Lyon and host Brett Drummond discuss highlights of ECTRIMS' new Pre-Day on NMOSD, MOGAD, and other rare neurological conditions.
-
Misdiagnosing multiple sclerosis (MS) is not uncommon. Neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody disorder (MOGAD) can have clinical manifestations similar to MS. In this two-part episode, host Brett Drummond of MSTranslate speaks with Prof. Sara Mariotto of the University of Verona in Italy and Prof. Kazuo Fujihara of Fukushima Medical University in Japan about the latest research on the pathogenesis of these diseases, diagnostic criteria, potential treatment approaches, and any learnings that may be translated to MS.
-
Misdiagnosing multiple sclerosis (MS) is not uncommon. Neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody disorder (MOGAD) can have clinical manifestations similar to MS. In this two-part episode, host Brett Drummond of MSTranslate speaks with Prof. Sara Mariotto of the University of Verona in Italy and Prof. Kazuo Fujihara of Fukushima Medical University in Japan about the latest research on the pathogenesis of these diseases, diagnostic criteria, potential treatment approaches, and any learnings that may be translated to MS.
-
The following episode has been produced by the European Academy of Neurology (EAN) in collaboration with the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), and has been published on both the EAN and ECTRIMS Podcast channels to ensure our joint communities have access to it.
In this episode of eanCast: Weekly Neurology, host Melinda Magyari is joined by ECTRIMS Podcast host Brett Drummond to talk about the ECTRIMS-EAN Vaccination Consensus Statement with lead author Susana Otero of the Department of Preventive Medicine and Epidemiology, Vall d'Hebron Barcelona Hospital, Barcelona, Spain and the Multiple Sclerosis Centre of Catalonia (Cemcat).
Read the full article here.
-
Multiple sclerosis (MS) is a complex and multifaceted neurological disorder. While MS has a genetic component, it is not a classic genetic disease. For this reason, a large amount of research has been done to identify environmental factors that may also be involved. In this episode, host Brett Drummond of MSTranslate talks with Emmanuelle Waubant, Professor of Neurology and Paediatrics at the University of California, San Francisco, about the latest findings on the role that environmental, genetic, and epigenetic risk factors play in MS.
-
The next major step forward in the management of MS involves finding treatments that can repair damaged myelin. If successful, it would offer the potential to start to reverse some of the symptoms experienced by people living with MS. Bruno Stankoff, a neurologist of the Pitié-Salpêtrière Hospital in Paris and vice president of ECTRIMS, and Gianvito Martino, scientific director of the San Raffaele Scientific Institute in Milan, discuss this important MS research area with host Brett Drummond of MSTranslate.
-
People living with MS want to be able to improve their quality of life and take control of a disease that is often filled with uncertainty. In this space, no topic has generated more interest or discussion than lifestyle modifications such as diet and exercise. What is the current evidence on how effective they can be at helping manage the disease? Robert Motl, professor of kinesiology and nutrition, and rehabilitation sciences at University of Illinois-Chicago, and Kathryn Fitzgerald, assistant professor of neurology at Johns Hopkins University, join host Brett Drummond of MStranslate.
-
While multiple sclerosis (MS) has been traditionally described as a disease of young adults, the significant improvements in treatments over the past few decades has meant that researchers and clinicians are now increasingly handling questions related to the impact of ageing.
In this episode, host Brett Drummond of MSTranslate talks with Anneke Van Der Walt, Director of MS and Neuroimmunology and Neuro-ophthalmology at Alfred Health in Melbourne, Australia and lead of the MS and Neuro-ophthalmology Research Group at the School of Translational Medicine, Monash University; and Professor Frederik Barkhof, Chair of Neuroradiology, Brain Repair & Rehabilitation at University College London's Queen Square Institute of Neurology and Professor in Neuroradiology at the Department of Radiology & Nuclear Medicine at VUmc in Amsterdam, on the key takeaways from a recent international workshop on ageing.
-
Artificial intelligence (AI) can be a powerful tool to help enhance our understanding of MS disease processes, improve our diagnostic accuracy, better predict disease course, and identify optimal treatments. How is AI being used in MS research currently and what may it be able to do in the future? Host Alan Thompson, Editor in Chief of MS Journal, talks with Arman Eshaghi of the Queen Square Institute of Neurology, University College London, and Daniel Ontaneda of the Cleveland Clinic Neurological Institute’s Mellen Center for Multiple Sclerosis in the United States.
- もっと表示する
